DALLAS, Tx. – November 7, 2024 – Johnson & Johnson MedTech, a global leader in orthopaedic technologies and solutions, will showcase its comprehensive portfolio of products and data-enabled solutions at this year’s American Association of Hip and Knee Surgeons (AAHKS) 2024 Annual Meeting in Dallas. Presentations and demonstrations will feature innovative products and data-driven solutions designed to improve surgical accuracy and help deliver better patient outcomes.
“2024 has been a remarkable year of progress for Johnson & Johnson MedTech, marked by numerous clearances, launches, and strategic collaborations. Most notably, this was the single most successful year for major launches for the VELYS™ Enabling Tech portfolio,” said Aldo Denti, Company Group Chairman, Orthopaedics, Johnson & Johnson MedTech. “Through our comprehensive procedural solutions, we are driving meaningful improvements in patient outcomes while making surgeries more precise and efficient. These advancements reflect our deep collaboration with surgeons and our dedication to transforming care across joint procedures.”
Key Innovations at AAHKS 2024:
- VELYS™ Robotic-Assisted Solution for Unicompartmental Knee Arthroplasty (UKA) – CT scan-free technology enables precise, surgeon-controlled implant placement and alignment1-2 for partial knee replacements while preserving soft tissue, predicting joint stability, and supporting personalized knee function recovery for each patient.3
- WATSON EXTRACTION SYSTEM™ – Simplifies femoral implant removal and revision.4,5 It is designed to reduce surgery time, improve predictability, and potentially avoid more complex procedures like Extended Trochanteric Osteotomies,6 using patented single-use, curved blades and reusable instruments for precision and efficiency.4
- VELYS™ Hip Navigation with CUPTIMIZE™ Advanced Hip-Spine Analysis & Guidance – Next-generation hip-spine analysis solution that provides an orientation of the acetabular component which aims to reduce the risk of edge loading and implant-implant impingement. It uses an algorithm that accounts for common risk factors and alerts the user to elevated dislocation risk.7
VELYS™ UKA application and WATSON EXTRACTION SYSTEM™ will all be available by the end of the year, while CUPTIMIZE™ Hip-Spine Analysis is currently available in the United States.*
Johnson & Johnson MedTech will host several presentations, panel discussions, hands-on training labs, and live demonstrations throughout the AAHKS meeting. Attendees can learn more at Booth #708 or online.
Orthopaedic Solutions from Johnson & Johnson MedTech
Across Johnson & Johnson, we are tackling the world’s most complex and pervasive health challenges. In Orthopaedics, we are on a mission to keep people moving by leveraging our deep expertise in joint reconstruction, robotics and enabling tech, spine, sports, trauma, and extremities, to develop the next generation of medtech solutions. We offer one of the most comprehensive Orthopaedics portfolios in the world that helps heal and restore movement for the millions of patients we serve. For more, visit our website or follow us at @jjmt_ortho and on LinkedIn.
About Johnson & Johnson
At Johnson & Johnson, we believe health is everything. Our strength in healthcare innovation empowers us to build a world where complex diseases are prevented, treated, and cured, where treatments are smarter and less invasive, and solutions are personal. Through our expertise in Innovative Medicine and MedTech, we are uniquely positioned to innovate across the full spectrum of healthcare solutions today to deliver the breakthroughs of tomorrow, and profoundly impact health for humanity. Learn more about our MedTech sector’s global scale and deep expertise in cardiovascular, orthopedics, surgery and vision solutions at https://thenext.jnjmedtech.com. Follow us at @JNJMedTech and on LinkedIn. DePuy Synthes Products, Inc. is a Johnson & Johnson MedTech company.
Cautions Concerning Forward-Looking Statements
This press release contains “forward-looking statements” as defined in the Private Securities Litigation Reform Act of 1995 regarding the KINCISE™ 2 Surgical Automated System, VELYS™ Robotic-Assisted Solution, WATSON EXTRACTION SYSTEM™ and VELYS™ Hip Navigation with CUPTIMIZE™ Advanced Hip-Spine Analysis. The reader is cautioned not to rely on these forward-looking statements. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or known or unknown risks or uncertainties materialize, actual results could vary materially from the expectations and projections of DePuy Synthes Products, Inc., and/or Johnson & Johnson. Risks and uncertainties include, but are not limited to: uncertainty of commercial success; challenges to patents; competition, including technological advances, new products and patents attained by competitors; manufacturing difficulties and delays; product efficacy or safety concerns resulting in product recalls or regulatory action; changes to applicable laws and regulations, including global health care reforms; changes in behavior and spending patterns of purchasers of health care products and services; and trends toward health care cost containment. A further list and descriptions of these risks, uncertainties and other factors can be found in Johnson & Johnson’s Annual Report on Form 10-K for the fiscal year ended December 31, 2023, including in the sections captioned “Cautionary Note Regarding Forward-Looking Statements” and “Item 1A. Risk Factors,” and in Johnson & Johnson’s subsequent Quarterly Reports on Form 10-Q and other filings with the Securities and Exchange Commission. Copies of these filings are available online at www.sec.gov, www.jnj.com or on request from Johnson & Johnson. Neither of DePuy Synthes Products, Inc., nor Johnson & Johnson undertakes to update any forward-looking statement as a result of new information or future events or developments.
*CUPTIMIZE and CUPTIMIZE Advanced are only available in the USA
The third-party trademarks used herein are the trademarks of their respective owners.
Important Information: Prior to use, refer to the instructions for use supplied with the device(s) or indications, contraindications, warnings and precautions.
© Johnson & Johnson and its affiliates 2024. All rights reserved. US_DPS_ALLD_392662
Footnotes
1 DePuy Synthes VELYS ™ Robotic-Assisted Solution for Unicompartmental Knee Rev-C Surgical Technique Guide. January 2024.
Windchill #501433682
2 DePuy Synthes VELYS ™ Robotic-Assisted Solution for Unicompartmental Knee Summative Evaluation Report. December 2023.
Windchill #103414383.
3 Hunter M., et al., Influence of Soft Tissue Releases on 2 Year Outcomes in Total Knee Arthroplasty and Rate of Soft Tissue
Releases in Robotic-Assisted Surgery. Current Concepts in Joint Replacement, Dec 2022. Poster No P-124.
4 Sagers et al. Removing Well-Fixed, Collared and Noncollared Tapered Hip Stems Without an Extended Trochanteric Osteotomy
Using a Novel Stem Removal System. Arthroplasty Today 11 (2021) 146e150
5 Saloman et al. The Watson Extraction System for removal of well-fixed femoral stems: A retrospective review of 10 cases. Journal
of Orthopaedics 43 (2023) 6-10
6 Email communication. Dr Jose Rivera. Simplex Designs.5th September 2024.
7 DePuy Synthes. Dynamo Hip User Guide vH.2. September 27, 2023. Windchill #501068319.
Media Contact:
Lindsey Diaz-MacInnis
ldiazmac@its.jnj.com